Celsion Corporation (CLSN)

[cameron12x]

The P3 results may not have been statistically relevant in the specific and narrow context of the definition of the trial, but I'd also harken to say that 300/700 patients "showing marked improvement" if the RFA was done for 45 minutes or more is VERY RELEVANT.

And the results do pave a path for another P3 trial (if not a limited approval in the absence of one). The reality is that this most recent trial was in truth a VERY LARGE P2 trial. I have no doubt that Thermodox is effective (when administered properly) and will eventually be licensed and approved by the FDA.

Patience, grasshopper.